MSN on MSN

Enliven Therapeutics reports positive phase 1 CML data and FDA alignment for phase 3 trial (ELVN)

Updated ELVN-001 results showed strong molecular response rates in previously treated CML patients, while the FDA aligned ...

Revolution Medicines reports phase 3 win in pancreatic cancer

Revolution Medicines (RVMD) reported Phase 3 clinical trial results showing its experimental cancer drug daraxonrasib ...

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that dat ...
EurekAlert!

Mount Sinai dermatologist reports Phase 3 success for rocatinlimab in moderate-to-severe eczema

New York, NY (November 25, 2025) – An international team of investigators led by Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of ...
Morningstar

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

DUBLIN, March 3, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced topline results from the Phase 3 CYPRESS study evaluating the ...
Seeking Alpha

Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026

Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...